Preventing bladder dysfunction after radical hysterectomy in | Figure 1

%27%3e%3cg%20id=%27Group-14%27%20transform=%27translate(13.000000,%20103.176124)%27%3e%3cg%20id=%27Group-Copy-5%27%20transform=%27translate(0.000000,%20182.676124)%27%3e%3crect%20id=%27Rectangle-8%27%20fill=%27%23E2E0DE%27%20x=%270%27%20y=%270%27%20width=%2736%27%20height=%2736%27%20rx=%2718%27%3e%3c/rect%3e%3cpath%20d=%27M28,27.6503435%20C28,22.127496%2023.5228474,17.6503435%2018,17.6503435%20C12.4771525,17.6503435%208,22.127496%208,27.6503435%20M18,16.3472505%20C20.8165136,16.3472505%2023.099749,14.0640151%2023.099749,11.2475015%20C23.099749,8.43098783%2020.8165136,6.1477524%2018,6.1477524%20C15.1834863,6.1477524%2012.9002509,8.43098783%2012.9002509,11.2475015%20C12.9002509,14.0640151%2015.1834863,16.3472505%2018,16.3472505%20Z%27%20id=%27Combined-Shape%27%20fill=%27%23FFFFFF%27%20fill-rule=%27nonzero%27%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)

Deleted account

Some actions are only available when you log in.

Report case

Report this to our moderators

Preventing bladder dysfunction after radical hysterectomy in women with early‐stage cervical cancer

You can view up to 4 cases without signing up Sign up for unlimited access

Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage cervical cancer

The issue

Radical hysterectomy with pelvic lymphadenectomy (removal of the uterus (womb) with its surrounding tissues and lymph glands in the pelvis) is the treatment for early‐stage cervical cancer (when cancer is still within the cervix and upper vagina, without spread into nearby tissues). Bladder dysfunction (problems with the way the bladder holds and releases urine) is a common problem following radical hysterectomy, caused by the damage to the nerves controlling urination.

The aim of the review

To assess the usefulness and safety of treatment to prevent bladder dysfunction following radical hysterectomy in women with early‐stage cervical cancer. We searched the scientific databases for randomised controlled trials (studies in which people or groups of people are allocated by chance to two or more groups, treating them differently) published to April 2020.

Main findings

We found four studies that met the inclusion criteria. One study compared a medication called bethanechol to placebo (a substance that has no therapeutic effect, used as a control in testing drugs). Three studies compared suprapubic catheterisation (insertion of a flexible tube (catheter) into the bladder through a cut in the lower abdomen to drain urine) with intermittent self‐catheterisation (insertion of a catheter via the urethra, into the bladder at intervals throughout the day).

Bethanechol versus placebo

Bethanecol may reduce the chance of bladder dysfunction by lowering the volume of post‐void residual urine, assessed at one month after surgery. However, the certainty of this evidence is very low and further studies have the potential to better inform this outcome.

Suprapubic catheterisation versus intermittent self‐catheterisation

There was insufficient evidence to indicate the effectiveness of suprapubic catheterisation and intermittent self‐catheterisation for preventing bladder dysfunction. Very‐low certainty evidence noted no difference between these two treatments in the risk of an unfavourable result and urinary tract infections during the first month after surgery.

Conclusions

None of the included studies reported rate of spontaneous voiding recovery one week after surgery, time to a post‐void residual volume of urine of 50 mL or less, or post‐void residual urine volume at 6 and 12 months after surgery, all of which are important outcomes for assessing postoperative bladder dysfunction. Limited evidence suggested that bethanechol may prevent bladder dysfunction after radical hysterectomy by lowering post‐void residual urine volume. The certainty of this evidence, however, was very low. The effectiveness of different types of postoperative urinary catheterisation (suprapubic and intermittent self‐catheterisation) remains unproven.

Read the full Cochrane Review here

Comment

Sign up to add a comment

More about this case

ResolvedVerified literature

Why you should join Figure 1

Sign up to explore now

Similar cases

\ \ Review question\ In people with cancer of the inner lining of the bladder, how do two different medicines, that are called Bacillus Calmette‐Guérin (BCG) and mitomycin (MMC), that are put into the bladder, after the tumour is taken out, compare?\ Background\ Tumours of the superficial layers of the bladder, so‐called non‐muscle‐invasive bladder cancer, are treated by putting small instruments into the bladder and shaving them out. This works well but these tumours often come back. When they do come back they can be more aggressive and advanced than before. Different types of medicines put into the bladder afterwards can make that happen less often, with BCG and MMC being those used most often. We are not sure how the two treatments compare when it comes to wanted and unwanted effects.\ Study characteristics\ The content of this review is current to September 2019. We included only studies where chance determined what treatment people in the study would get.\ Key results\ We found 12 studies including 2932 people who matched our question.\ We found that BCG may lead to similar risk of dying from any cause over time (low‐quality evidence), but may increase the risk of serious unwanted effects (low‐quality evidence), although it is possible that it does not make a difference.\ BCG may reduce the risk that the tumour comes back over time (low‐quality evidence), although it is possible that it does not make a difference.\ BCG may have little or no effect on the risk that the tumour gets worse over time (low‐quality evidence).\ We found no data on quality of life.\ Quality of the evidence\ The quality of the evidence was consistently rated as low, meaning that our confidence is limited, and future research may change these findings.](https://app.figure1.com/case-detail/23b5def6-0f1d-4593-b628-e9e7be563f76)

\ \ Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity in adults undergoing non‐cardiac surgery\ This review assessed evidence from randomized controlled trials (RCTs) on whether beta‐blockers reduce deaths or other serious events when given to people undergoing surgery other than heart surgery. The findings for heart surgery are covered in another review.\ Background\ Surgery increases stress in the body, which responds by releasing the hormones adrenaline and noradrenaline. Stress from surgery can lead to death or other serious events such as heart attacks, stroke, or an irregular heartbeat. For surgery that does not involve the heart, an estimated 8% of people may have injury to their heart around the time of surgery. Beta‐blockers are drugs that block the action of adrenaline and noradrenaline on the heart. Beta‐blockers can slow down the heart, and reduce blood pressure, and this may reduce the risk of serious events. However, beta‐blockers may lead to a very low heart rate or very low blood pressure which could increase the risk of death or a stroke. Prevention of early complications after surgery is important, but using beta‐blockers to prevent these complications is controversial.\ Study characteristics\ The evidence is current to 28 June 2019. We included 83 RCTs with 14,967 adults who were undergoing different types of surgery other than heart surgery. Eighteen studies are awaiting classification (because we did not have enough details to assess them), and three studies are ongoing. The types of beta‐blockers used in the studies were: propranolol, metoprolol, esmolol, landiolol, nadolol, atenolol, labetalol, oxprenolol, and pindolol. Studies compared these beta‐blockers with either a placebo (disguised to look like a beta‐blocker but containing no medicine) or with standard care.\ Key results\ Beta‐blockers may make little or no difference to the number of people who die within 30 days of surgery (16 studies, 11,446 participants; low‐certainty evidence), have a stroke (6 studies, 9460 participants; low‐certainty evidence), or experience ventricular arrhythmias (irregular heartbeat rhythms, starting in the main chambers of the heart, that are potentially life‐threatening and may need immediate medical treatment; 5 studies, 476 participants; very low‐certainty evidence). We found that beta‐blockers may reduce atrial fibrillation (an irregular heartbeat, starting in the atrial chambers of the heart, that increases the risk of stroke if untreated; 9 studies, 9080 participants; low certainty‐evidence), and the number of people who have a heart attack (12 studies, 10,520 participants; low‐certainty evidence). However, taking beta‐blockers may increase the number of people who experience a very low heart rate (49 studies, 12,239 participants; low‐certainty evidence), or very low blood pressure (49 studies, 12,304 participants; moderate‐certainty evidence), around the time of surgery.\ In a few studies, we also found little or no difference in the number of people who died after 30 days, who died because of a heart problem, or had heart failure. We found no evidence of whether beta‐blockers alter the length of time in hospital.\ No studies assessed whether people who were given beta‐blockers had a better quality of life after heart surgery.\ Certainty of the evidence\ The certainty of the evidence in this review was limited by including some studies that were at high risk of bias, and we noticed that some of our findings were different if we only included placebo‐controlled studies or studies that reported how participants were randomized. We also found one large, well‐conducted, international study that had different findings to the smaller studies. It showed a reduction in heart attacks and an increase in stroke and all‐cause mortality when beta‐blockers were used, whilst the other studies did not show a clear effect. We were also less certain of the findings for outcomes with few studies, such as for ventricular arrhythmias.\ Conclusion\ Although beta‐blockers may make little or no difference to the number of people who die within 30 days, have a stroke, or have ventricular arrhythmias, they may reduce atrial fibrillation and heart attacks. Taking beta‐blockers may increase the number of people with a very low heart rate or very low blood pressure around the time of surgery. Further evidence from large, placebo‐controlled trials is likely to increase the certainty of these findings, and we recommend the assessment of impact on quality of life.](https://app.figure1.com/case-detail/28d23f1e-5e1f-4ccf-bacf-ddde5b44d221)

\ \ 74 years old female Known case of HTN,T2DM and Primary Hypothyroidism recently diagnosed with Chronic urinary retention. (Significant PVRU 1250ml). Urologist was consulted. Patient was catheterised and gradual decompression of urinary bladder was done @ 150ml /hour. Tab Veltam 0.4 mg once daily and Tab Urotone DS twice daily was started. Pt was kept on Foley's catheter for 2 weeks.\ After 2 weeks Urologist advised to remove catheter and do clean intermittent catheterisation. But as the patient was unable to do CIC , foley's catheter was continued for 2 months.\ Now after 2 months voiding trial was given and usg was done 2 days post catheter removal which shows a Post void residual urine volume of 157ml.\ Query.\ Is 157 ml of PVRU acceptable or patient still needs catheterisation.](https://app.figure1.com/case-detail/320304c1-5565-4ee7-b8a9-11a58f1462a4)

\ \ Review question\ What is the best way to treat women whose stress urinary incontinence is not cured or recurs after surgery to insert a tape underneath the bladder outlet (midurethral tape)?\ Background\ Stress urinary incontinence (SUI) is the loss of urine when a person coughs or exercises. It can be caused by damage to the pelvic floor muscles or their nerve supply, particularly during childbirth. Simple treatments, such as exercising pelvic floor muscles or medication, may be tried at first. If these methods have not worked, surgery is often performed, which can be done using a midurethral tape. This usually involves placing a tape made from polypropylene (a synthetic material like nylon that is used in some surgical stitches and other medical devices) underneath the bladder outlet. This operation is usually very successful, but not all women will be cured. There is currently no agreement amongst experts on how to treat women with recurrent stress urinary incontinence problems following unsuccessful midurethral tape surgery.\ How up‐to‐date is this review?\ The evidence is current up to 9 November 2018.\ Study characteristics\ Our search identified one study for this review, including a total of 341 women. Of these, just 46 women met our inclusion criteria by having undergone previous continence surgery with a midurethral tape or colposuspension (a type of surgery used to support the tissues around the neck of the bladder with stitches). This review only focused on the results from these 46 women, extracted from the overall trial results.\ Study funding sources\ The one included study was funded by the Henry Smith Charity. A published correction indicated commercial support from the manufacturer of a device used in the study, which could be a source of bias.\ Key results\ We wanted to assess the effects of conservative treatment (such as pelvic floor muscle training or bladder training), surgery and medication on the number of women who reported that their incontinence was improved or cured after treatment, along with other outcomes such as quality of life and adverse events. We were also interested in the effects on our outcomes of different types of midurethral tapes.\ Of the 46 eligible women in the included study, two‐thirds were reported to have received a midurethral tape in their first surgery. However, the data in the report did not differentiate between women who had previously undergone surgery with a midurethral tape and those who had had colposuspension. This means that we cannot be certain that the results were due to the midurethral tape, so we could not use the data in this review.\ We planned to summarise evidence about which treatments might be considered worthwhile uses of healthcare resources but we did not identify any studies that asked this question.\ Certainty of the evidence\ The lack of useable data means that we were unable to assess the certainty of the body of evidence.\ Authors' conclusions\ We did not find enough data to accurately assess the effects of any of the different management strategies for recurrent or persistent stress incontinence after failed midurethral tape surgery. Evidence from high‐quality studies is required to address this area of uncertainty.](https://app.figure1.com/case-detail/43d139a9-39bb-4000-994d-0d7447bdda8c)

Trending now

\ \ A 52-year-old man presented with a 20-minute history of chest pain radiating to the left shoulder and neck, associated with dyspnea and diaphoresis.\ He had a history of hypertension, long-term smoking, and a sedentary lifestyle.\ On physical examination, bibasilar crackles were noted on lung auscultation. An electrocardiogram (ECG) was performed in the primary care setting, and the patient was promptly referred to the emergency department.](https://app.figure1.com/case-detail/ae0fe999-6875-4474-94f0-ad823dbb9b3a)

\ \ A 28-year-old woman presented with a 3-day history of intense pruritus over the lower back. She reported no recent travel or exposure to new environments. She cares for a small kennel with approximately eight dogs rescued from the streets.\ Physical examination revealed multiple small vesicles, some clustered and others scattered, predominantly involving the lumbar region and the left gluteal area.](https://app.figure1.com/case-detail/c271070f-2bc7-4052-9895-635277e1a7d5)

\ \ A 4-month-old male infant presented with skin lesions localized to the chin for the past 3 days. Physical examination revealed multiple small pustules with surrounding inflammatory signs on the chin, along with a few scattered papules on the chest.](https://app.figure1.com/case-detail/48f41642-b9db-4089-b120-a94ee52328de)

\ \ patient in late teens presenting after a collapse, no chest pain, no previous cardiac history, no history of sudden death in family, are there any features in this ekg that would warrant further work-up or is this just a pediatric ekg?](https://app.figure1.com/case-detail/2af390e1-ace8-40ed-ba1c-98fb2d72f4c5)